Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02227758
Other study ID # NM-11-059-EU-ON
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 2012
Est. completion date December 2015

Study information

Verified date January 2019
Source Abbott Medical Devices
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to evaluate the long-term safety and performance of neurostimulation for the treatment of intractable chronic migraine as well as to detect infrequent complications or problems only apparent in "real-world" practice


Recruitment information / eligibility

Status Completed
Enrollment 112
Est. completion date December 2015
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility - Patient is 18 years of age or older.

- Patient has signed and received a copy of the Informed Consent form;

- Patient has been implanted with a St. Jude Medical CE approved implantable neurostimulation system for the treatment of intractable chronic migraine:

- Patient diagnosed with chronic migraine (15 or more days per month with headache lasting at least 4 hours per day)

- Patient has failed three or more preventative drugs for treatment of their migraine

- Patient has at least moderate disability determined using a validated migraine disability instrument [e.g., MIDAS >11 or HIT-6 >56]

Exclusion Criteria:

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Belgium Centre Hospitalier Régional de la CITADELLE Liège
Belgium Heilig Hartziekenhuis Roeselare West-Vlaanderen
Germany Neurologische Klinik und Poliklinik Charité Campus Mitte Berlin
Germany Klinikum Delmenhorst GmbH Delmenhorst Großherzogtum Oldenburg
Germany Universitätsklinikum Düsseldorf Düsseldorf Nordrhein-Westfalen
Germany Praxis fur Neurologie, Spezielle Schmerztherapie, Psychotherapie Essen Nordrhein-Westfalen
Germany Universitätsklinikum Essen Essen Nordrhein-Westfalen
Germany Schmerzklinik und Praxis an der Schmerzklinik Kiel Kiel Schleswig-Holstein
Germany Migräne and Kopfschmerzklinik Königstein Königstein Saksen
Luxembourg Centre Hospitalier de Luxembourg Luxembourg
Spain Hospital Puerta de Hierro Madrid
Spain Hospital Universitario Madrid
Spain Hospital Universitario Virgen del Rocio Sevilla Andalucia
Sweden Karolinska Hospital Stockholm Stockholms Län
United Kingdom Seacroft Hospital Leeds Yorkshire
United Kingdom King's College Hospital London
United Kingdom Royal London Hospital London Royal London Hospital
United Kingdom John Radcliffe hospital Oxford Oxfordshire

Sponsors (1)

Lead Sponsor Collaborator
Abbott Medical Devices

Countries where clinical trial is conducted

Belgium,  Germany,  Luxembourg,  Spain,  Sweden,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse Events (First 12 Weeks) Events were classified as hardware related when a malfunction or migration of any device component including leads, extensions, IPG's, occurred. Events will classified as biological in cases where there was a biological reaction (hematoma, pain, etc.) to either the device or the surgical procedure to implant the device. Events were classified as stimulation related if the event was known to be caused by stimulation. 3 months
Primary Headache Pain Relief Patient reported headache pain relief in percentage for the previous month; patients were asked about their pain relief in percentage in the previous month; patient were asked "in the last month", how much headache relief has the implant provided (0% represents no relief, 100% represents complete relief) 3 months
Primary Headache Days Percentage change in number of Headache days from Baseline to 3 Months. Headache days are the amount of days the subject had an headache in the previous 3 months as captured by the MIDAS questionnaire. 3 months
Primary Migraine Disability Percentage change in Midas score from Baseline to 3 Months. The Midas questionnaire consists out of 5 questions to be answered by the patient. Three questions address the number of missed days due to headache in school or paid work, household work and family, social or leasure activities. The two remaining questions document the number of additional days with significant limitations to activity (defined as at least 50% reduced productivity) in the domains of employment and household work. The total score is the sum of days completed for questions 1-5. Midas score ranges from 0 to 21+ with higher values indicating greater disability. 3 months
Primary Patient Satisfaction Patients very satisfied or satisfied with the headache relief since the implant. Patients were asked about their satisfaction (very satisfied, satisfied, neither satisfied or dissatisfied, unsatisfied, very unsatisfied) 3 months
Primary Physician Satisfaction Patients for who the physician is very satisfied or satisfied with the patient headache relief since the implant. Physicians were asked about their satisfaction (very satisfied, satisfied, neither satisfied or dissatisfied, unsatisfied, very unsatisfied) 3 months
Primary Quality of Life Patients who reported the change in overall quality of life since the implant with greatly improved or improved. Patients were asked about their change in overall quality of life (Greatly improved, improved, neither improved or deteriorated, deteriorated, greatly deteriorated) 3 months
Primary Quality of Life Patients for who the physician reported the change in overall quality of life of the patient since the implant with greatly improved or improved. Physicians were asked about the change in overall quality of life of the patient(Greatly improved, improved, neither improved or deteriorated, deteriorated, greatly deteriorated) 3 months